Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Vascular Disorders
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Vascular Disorders
    TopAbstracts in Vascular Disorders 10/02/2008 - (DGNews)
    Beta-Blockers Reduce Mortality in Patients With COPD After Vascular Surgery - (DGNews)
    3-D CT Scans Provide More Comprehensive View of Complex Varicose Veins - (DGNews)
    TopAbstracts in Vascular Disorders 09/18/2008 - (DGNews)
    Minimally-Invasive Aortic Valve Bypass Benefits High-Risk Elderly Patients - (DGNews)

    News archive

     Recent webcasts/CME - Vascular Disorders
    • Improving the Standard of Care in Acute Hypertension
    • Understanding Metabolic Dysfunction in HIV
    • Inhibiting Angiotensin II at the Vessel Wall: Impact on Atherosclerosis
      PVD: Controversies in Carotid, Renal and Peripheral Arterial Therapies
      Recognition and Management of Leg Disorders Across the Spectrum

      Webcasts/CME archive

       Recent cases - Vascular Disorders
        Direct Spread of Thyroid Follicular Carcinoma to the Parotid Gland and the Internal Jugular Vein: A Case Report
        Computerized Tomographic Angiography for Preoperative Assessment of the Superficial Temporal Artery for External Carotid Artery to Internal Carotid Artery Bypass: A Case Report
        Unexpected Limited Chronic Dissection of the Ascending Aorta
        Mycobacterium Tuberculosis Aortic Graft Infection with Recurrent Hemoptysis: A Case Report
        Takayasu's Arteritis Presenting as a Dissecting Aortic Aneurysm History: A Case Report

        Cases archive
          




        my personal edition > vascular disorders > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Angiogenic Therapy Appears To Reduce Claudication

        A DGReview of :"Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial"
        Lancet

        06/13/2002
        By Harvey McConnell


        Angiogenic therapy which combines genes, proteins, and other molecular agents to stimulate growth of new blood vessels has demonstrated improvement in peripheral blood flow for patients with intermittent claudication caused by atherosclerosis.

        In a trial involving 174 patients at 22 centres across the United States, investigators using recombinant fibroblast growth factor-2 (rFGF-2) have provided evidence of clinical therapeutic angiogenesis by intra-arterial infusion of an angiogenic protein.

        The Therapeutic Angiogenesis With FGF for Intermittent Claudication (TRAFFIC) trial -- a phase II randomized double-blind controlled study -- was directed by Dr Robert Lederman, then at the University of Michigan and now at the National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, and Dr Brian Annex, Duke University Medical Center, Durham, North Carolina.

        Investigators point out that the protein recombinant fibroblast growth factor-2 (rFGF-2) can cause growth and proliferation of blood vessels from existing vascular structures. They aimed to test the hypothesis that rFGF-2 improves treadmill performance in patients with intermittent claudication of the leg caused by infra-inguinal obstructive atherosclerosis.

        The rFGF-2 used in the trial was a 146 amino acid, non-glycosylated, monomeric, 16·5 kDa protein, which is produced in genetically engineered yeast.

        Investigators enrolled 190 patients with intermittent claudication of the calf muscle caused by atherosclerosis. They were randomly assigned bilateral intra-arterial infusions of placebo on days one and 30 (the control group); rFGF-2 (30 g/kg) on day one and placebo on day 30 (single-dose group); or rFGF-2 (30 g/kg) on days one and 30 (double-dose group). Data were available for 174 of the patients.

        Peak walking time at 90 days was increased by 0.6 minutes with placebo, by 1.77 minutes with single-dose rFGF-2, and by 1.54 minutes with double-dose rFGF-2. Two doses over 30 days were not superior to one dose, but alternate dosing regimens could warrant further consideration, the investigators add.

        The TRAFFIC trial did not look at the effects of other treatments for intermittent claudication, particularly concurrent structured exercise or cilostazol. In addition, there was no significant difference in claudication onset time or quality of life between treatment groups.

        In a separate comment on the trial, Dr Annex said: "This is the third large multi-center randomized placebo-controlled trial looking at the therapeutic use of an angiogenic agent and the first to show a positive result in its primary endpoint. This study provides the strongest and most convincing data to date that an angiogenic agent can have a positive effect in humans."
        Lancet 2002; 359: 2053-58. "Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send